1. patients with other diseases that may affect, in the opinion of study researchers, the implementation of the study or the observation of the efficacy data; 2. patients with severe coronavirus disease 2019 (covid-19), that is based on "guidance of diagnosis and treatment for patients with coronavirus disease 2019 (covid-19) (procedural version 5 amendment)" with respect to the criteria for clinical severity classification; 3. female patients with known pregnancy and in lactation at screening; 4. patients with previous allergies to t89 or radix salvia miltiorrhizae, radix notoginseng and borneol; 5. any other condition that, in the opinion of the investigator, may affect the conduct of the study, reduce compliance or increase the risk of patients.

1. patients with other diseases that may affect, in the opinion of study researchers, the implementation of the study or the observation of the efficacy data; 2. patients with severe coronavirus disease 2019 (covid-19), that is based on "guidance of diagnosis and treatment for patients with coronavirus disease 2019 (covid-19) (procedural version 5 amendment)" with respect to the criteria for clinical severity classification; 3. female patients with known pregnancy and in lactation at screening; 4. patients with previous allergies to t89 or radix salvia miltiorrhizae, radix notoginseng and borneol; 5. any other condition that, in the opinion of the investigator, may affect the conduct of the study, reduce compliance or increase the risk of patients.

patients with other diseases that may affect, in the opinion of study researchers, the implementation of the study or the observation of the efficacy data; patients with severe coronavirus disease 2019 (covid-19), that is based on "guidance of diagnosis and treatment for patients with coronavirus disease 2019 (covid-19) (procedural version 5 amendment)" with respect to the criteria for clinical severity classification; female patients with known pregnancy and in lactation at screening; patients with previous allergies to t89 or radix salvia miltiorrhizae, radix notoginseng and borneol; any other condition that, in the opinion of the investigator, may affect the conduct of the study, reduce compliance or increase the risk of patients.

patients with other diseases that may affect, in the opinion of study researchers, the implementation of the study or the observation of the efficacy data; patients with severe coronavirus disease 2019 (covid-19), that is based on "guidance of diagnosis and treatment for patients with coronavirus disease 2019 (covid-19) (procedural version 5 amendment)" with respect to the criteria for clinical severity classification; female patients with known pregnancy and in lactation at screening; patients with previous allergies to t89 or radix salvia miltiorrhizae, radix notoginseng and borneol; any other condition that, in the opinion of the investigator, may affect the conduct of the study, reduce compliance or increase the risk of patients.

1. patients with other diseases that may affect, in the opinion of study researchers, the implementation of the study or the observation of the efficacy data; 2. patients with severe coronavirus disease 2019 (covid-19), that is based on "guidance of diagnosis and treatment for patients with coronavirus disease 2019 (covid-19) (procedural version 5 amendment)" with respect to the criteria for clinical severity classification; 3. female patients with known pregnancy and in lactation at screening; 4. patients with previous allergies to t89 or radix salvia miltiorrhizae, radix notoginseng and borneol; 5. any other condition that, in the opinion of the investigator, may affect the conduct of the study, reduce compliance or increase the risk of patients.

1. patients with other diseases that may affect, in the opinion of study researchers, the implementation of the study or the observation of the efficacy data; 2. patients with severe coronavirus disease 2019 (covid-19), that is based on "guidance of diagnosis and treatment for patients with coronavirus disease 2019 (covid-19) (procedural version 5 amendment)" with respect to the criteria for clinical severity classification; 3. female patients with known pregnancy and in lactation at screening; 4. patients with previous allergies to t89 or radix salvia miltiorrhizae, radix notoginseng and borneol; 5. any other condition that, in the opinion of the investigator, may affect the conduct of the study, reduce compliance or increase the risk of patients.